EnGeneIC

About

EnGeneIC develops an antibody‑targeted EDV nanocell platform delivering chemotherapeutics, targeted drugs, and RNAi into tumor cells, operating from New York and Sydney and running Phase 1/2a oncology trials.

Mission

EnGeneIC is a biopharmaceutical company developing a proprietary EDV™ nanocell platform that delivers chemotherapeutics, molecularly targeted drugs, and RNA‑interference molecules directly into tumor cells. The company operates from New York City and Sydney and is led by Joint‑CEOs Himanshu Brahmbhatt, Ph.D., and Jennifer MacDiarmid, Ph.D. EnGeneIC completed a $10M Series B financing to advance clinical development of its antibody‑targeted nanocell technology. Planned uses include commencing a Phase 1/2a trial in recurrent glioblastoma in mid‑2015 in conjunction with a premier U.S. hospital and a personalized medicine trial at Royal North Shore Hospital in Sydney. It will also continue funding an ongoing Phase 1/2a mesothelioma trial in Australia, which is enrolling patients and expected to report preliminary safety data in Q2 2015. The company has established a U.S. base of operations in New York and appointed Anjan Chatterji as Executive Vice President of Corporate Development to operate from the New York office.

Quick Facts